PT  - JOURNAL ARTICLE
AU  - Lubinga, Solomon J
AU  - Payer, Tilman
AU  - Gregg, Meghann
AU  - Lee, Lydia
AU  - Allonby, Odette
AU  - García-Fernández, Llenalia
AU  - Hurteau, Jean
TI  - 588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
AID  - 10.1136/jitc-2023-SITC2023.0588
DP  - 2023 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - A668--A669
VI  - 11
IP  - Suppl 1
4099  - http://jitc.bmj.com/content/11/Suppl_1/A668.short
4100  - http://jitc.bmj.com/content/11/Suppl_1/A668.full
SO  - J Immunother Cancer2023 Nov 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.